Loading
TROP2 is on the surface of most breast and lung cancers. Sacituzumab govitecan and datopotamab deruxtecan are given without measuring it; a computational TROP2 score is being tested as a selector in lung cancer.
Sacituzumab govitecan (Trodelvy) is labelled for triple-negative and HR-positive HER2-negative breast cancer and urothelial cancer, datopotamab deruxtecan (Datroway) for HR-positive HER2-negative breast cancer and EGFR-mutant NSCLC, in both cases without a TROP2 test. The TROPION-Lung01 exploratory analysis introduced a quantitative continuous scoring (normalised membrane ratio) that separated responders in non-squamous NSCLC; it is being validated prospectively (TROPION-Lung12, NCT06564844 and other studies) and is not in any label.
In plain words · TROP2 is a surface glycoprotein present at high levels on most epithelial cancers (breast, lung, urothelial, gastric, pancreatic) and at low levels on normal tissue. It does not drive the cancer; it is a delivery address, used by the approved ADCs sacituzumab govitecan and datopotamab deruxtecan and by sacituzumab tirumotecan, with a TROP2 PET tracer in development to pick patients.
You will not be tested for TROP2 before sacituzumab govitecan or datopotamab deruxtecan; the labels do not require it because nearly all eligible cancers express it. A computerised TROP2 score is under study in lung cancer and may become a selection test later.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
The label names the antigen in the drug's description but does not require it to be measured before treatment; no approval threshold exists for this readout.
“TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate”
TRODELVY prescribing information (DailyMed)No approval uses this readout as a threshold.
Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.
Shares Non-small-cell lung cancer and the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.